In May 2008 the company reported, that although TOLAMBA showed a trend towards a reduction of the symptoms of ragweed allergic individuals relative to placebo, no statistical significance was achieved ( https://investors.dynavax.com/news-releases/news-release-details/dynavax-tolambatm-chamber-study-misses-primary-endpoint-company ).
1
—
—